Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,076 matching trials from the live ClinicalTrials.gov search.
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of British Columbia
Other
Eligibility
3 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Phoenix, Arizona • Aurora, Colorado • Denver, Colorado + 2 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Cystic Fibrosis and Endothelial Function: At Rest and During Exercise

NCT01772758
Conditions
Cystic Fibrosis
Interventions
BH4 5mg, BH4 20mg, Antioxidant Cocktail
Drug · Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
7 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Augusta, Georgia
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
52
States / cities
Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 47 more
Completed No phase listed Observational Accepts healthy volunteers

Pulmonary Fibrosis Contact Registry

NCT01935726
Conditions
Pulmonary Fibrosis of Any Cause, Primary Supporters/Caretakers of Patients With Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Cystic Fibrosis (CF)
Interventions
Not listed
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Months to 11 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Orange, California • Aurora, Colorado • Hollywood, Florida + 10 more
Conditions
Cystic Fibrosis
Interventions
Lung Clearance Index, MRI with PFP
Device · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Interstitial Lung Disease
Interventions
efzofitimod 450 mg, efzofitimod 270 mg, Placebo
Drug
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 10 more
Active, not recruiting Phase 4 Interventional

BEGIN Novel ImagiNG Biomarkers

NCT05517655
Conditions
Cystic Fibrosis
Interventions
129Xe
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 8 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Charlottesville, Virginia
Conditions
Cystic Fibrosis
Interventions
CF. DOC
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
1 Month to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Cystic Fibrosis
Interventions
Adults - CFPE Treatment
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
South Portland, Maine • Lebanon, New Hampshire
Conditions
Cough, Idiopathic Pulmonary Fibrosis
Interventions
Orvepitant Maleate, Placebo
Drug
Lead sponsor
Nerre Therapeutics Ltd.
Industry
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 13 more
Terminated Phase 1Phase 2 Interventional Results available

Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)

NCT02323100
Conditions
Cystic Fibrosis
Interventions
Ravicti low dose, Placebo
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Denver, Colorado • Baltimore, Maryland • Philadelphia, Pennsylvania
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Year to 16 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cystic Fibrosis (CF)
Interventions
Elexacaftor / Ivacaftor / Tezacaftor, therapeutic drug monitoring
Drug · Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
3 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Seattle, Washington
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
ND-L02-s0201 (Low Dose), ND-L02-s0201 (High Dose), Other: Placebo
Drug · Other
Lead sponsor
Nitto Denko Corporation
Industry
Eligibility
40 Years to 80 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
21
States / cities
Tucson, Arizona • Los Angeles, California • Northridge, California + 18 more
Conditions
Portopulmonary Hypertension, Pulmonary Hypertension, Cirrhosis, Liver
Interventions
Ambrisentan Pill, Tadalafil Pill
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Orleans, Louisiana
Conditions
Cystic Fibrosis
Interventions
Pioglitazone
Drug
Lead sponsor
Paul Beringer
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Cystic Fibrosis, Contraception, Physician-Patient Relations, Pregnancy Complications
Interventions
MyVoice:CF
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Chronic Rhinosinusitis (Diagnosis), Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 99 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Stanford, California • Aurora, Colorado + 6 more
Completed Early Phase 1 Interventional Accepts healthy volunteers

Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT

NCT03183570
Conditions
Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, Covid19 Pneumonia
Interventions
[18F]FP-R01-MG-F2
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Stanford, California
Conditions
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Interventions
BI 1839100, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Birmingham, Alabama • Lakewood, Colorado • Kissimmee, Florida + 14 more
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Deupirfenidone, Pirfenidone (PFD)
Drug
Lead sponsor
PureTech
Industry
Eligibility
40 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
16
States / cities
Palm Spring, California • Redding, California • Hialeah, Florida + 13 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilocarpine Microneedles for Sweat Induction (PMN-SI)

NCT04732195
Conditions
Cystic Fibrosis
Interventions
Pilocarpine microneedle patch, Pilocarpine Iontophoresis
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
7 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas